[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SG11201705116SA - Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof - Google Patents

Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof

Info

Publication number
SG11201705116SA
SG11201705116SA SG11201705116SA SG11201705116SA SG11201705116SA SG 11201705116S A SG11201705116S A SG 11201705116SA SG 11201705116S A SG11201705116S A SG 11201705116SA SG 11201705116S A SG11201705116S A SG 11201705116SA SG 11201705116S A SG11201705116S A SG 11201705116SA
Authority
SG
Singapore
Prior art keywords
tnf
receptor binding
necrosis factor
tumor necrosis
binding molecules
Prior art date
Application number
SG11201705116SA
Inventor
Beatrice Tien-Yi Wang
Max Allen Schwarzer
Bruce Alan Keyt
Ramesh Baliga
Original Assignee
Igm Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Igm Biosciences Inc filed Critical Igm Biosciences Inc
Publication of SG11201705116SA publication Critical patent/SG11201705116SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG11201705116SA 2015-01-20 2016-01-20 Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof SG11201705116SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562105323P 2015-01-20 2015-01-20
PCT/US2016/014153 WO2016118641A1 (en) 2015-01-20 2016-01-20 Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof

Publications (1)

Publication Number Publication Date
SG11201705116SA true SG11201705116SA (en) 2017-08-30

Family

ID=56417700

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201705116SA SG11201705116SA (en) 2015-01-20 2016-01-20 Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof
SG10202001779UA SG10202001779UA (en) 2015-01-20 2016-01-20 Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202001779UA SG10202001779UA (en) 2015-01-20 2016-01-20 Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof

Country Status (17)

Country Link
US (4) US10689449B2 (en)
EP (2) EP3750918A1 (en)
JP (4) JP7179464B2 (en)
KR (1) KR102435324B1 (en)
CN (1) CN107207601A (en)
AU (2) AU2016209324B2 (en)
CA (1) CA2972990A1 (en)
DK (1) DK3247728T3 (en)
ES (1) ES2806500T3 (en)
HU (1) HUE051013T2 (en)
IL (3) IL284430B2 (en)
NZ (1) NZ732922A (en)
PL (1) PL3247728T3 (en)
PT (1) PT3247728T (en)
SG (2) SG11201705116SA (en)
SI (1) SI3247728T1 (en)
WO (1) WO2016118641A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014332458B2 (en) 2013-09-05 2020-03-12 Igm Biosciences, Inc. Constant chain modified bispecific, penta- and hexavalent Ig-M antibodies
WO2015120474A1 (en) 2014-02-10 2015-08-13 Igm Biosciences, Inc. Iga multi-specific binding molecules
IL278350B (en) 2014-04-03 2022-06-01 Igm Biosciences Inc Modified j-chain
SG11201705116SA (en) 2015-01-20 2017-08-30 Igm Biosciences Inc Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof
HUE054642T2 (en) 2015-03-04 2021-09-28 Igm Biosciences Inc Cd20 binding molecules and uses thereof
KR102558839B1 (en) 2015-03-25 2023-07-25 아이쥐엠 바이오사이언스 인코포레이티드 Multivalent hepatitis B virus antigen-binding molecules and uses thereof
AU2016249404B2 (en) 2015-04-17 2021-01-21 Igm Biosciences, Inc. Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof
EP3355913B1 (en) 2015-09-30 2024-10-30 IGM Biosciences, Inc. Binding molecules with modified j-chain
CN108463472A (en) 2015-09-30 2018-08-28 Igm生物科学有限公司 The binding molecule of J- chains with modification
PT3455257T (en) 2016-05-09 2021-12-06 Igm Biosciences Inc Anti-pd-l1 antibodies
JP2019528683A (en) * 2016-07-20 2019-10-17 アイジーエム バイオサイエンシズ インコーポレイテッド Multimeric GITR binding molecules and uses thereof
JP7009448B2 (en) * 2016-08-12 2022-02-10 ヤンセン バイオテツク，インコーポレーテツド Fc genetically engineered anti-TNFR superfamily member antibody with enhanced agonist activity and how to use it
EP3360898A1 (en) * 2017-02-14 2018-08-15 Boehringer Ingelheim International GmbH Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
WO2018185247A1 (en) * 2017-04-06 2018-10-11 Universität Stuttgart Tumor necrosis factor receptor (tnfr) binding protein complex with improved binding and bioactivity
WO2018187702A2 (en) 2017-04-07 2018-10-11 Igm Biosciences A/S Modified human igm constant regions for modulation of complement-dependent cytolysis effector function
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. Multispecific molecules that bind to bcma and uses thereof
CN108251443A (en) * 2018-01-23 2018-07-06 深圳市人民医院 A kind of TNFRSF10C recombinant plasmids, preparation method and applications
WO2019157772A1 (en) * 2018-02-13 2019-08-22 和元生物技术（上海）股份有限公司 Anti-trailr2 antibody-toxin-conjugate and pharmaceutical use thereof in anti-tumor therapy
KR20200123782A (en) * 2018-02-26 2020-10-30 아이쥐엠 바이오사이언스 인코포레이티드 Use of multiple bonded anti-DR5 binding molecules in combination with chemotherapeutic agents for cancer treatment
AU2019227984A1 (en) 2018-03-01 2020-09-10 Igm Biosciences, Inc. IgM Fc and J-chain mutations that affect IgM serum half-life
CN112955465A (en) 2018-07-03 2021-06-11 马伦戈治疗公司 anti-TCR antibody molecules and uses thereof
US20210380701A1 (en) * 2018-10-23 2021-12-09 Igm Biosciences, Inc. MULTIVALENT IgM- AND IgA-Fc-BASED BINDING MOLECULES
EP3907240A4 (en) * 2019-08-02 2023-02-22 Jiangsu Simcere Pharmaceutical Co., Ltd. Anti-tnfr2 antibody and use thereof
US20230203119A1 (en) 2019-08-15 2023-06-29 Igm Biosciences, Inc. Immunostimulatory multimeric binding molecules
CN115443140A (en) * 2020-04-02 2022-12-06 苏州恒康生命科学有限公司 Human ROR-1 antibodies and anti-ROR-1-CAR-T cells
CN115485299A (en) 2020-04-22 2022-12-16 Igm生物科学股份有限公司 PD-1 agonist multimeric binding molecules
WO2022036495A1 (en) 2020-08-17 2022-02-24 Utc Therapeutics Inc. Lymphocytes-antigen presenting cells co-stimulators and uses thereof
JP7203870B2 (en) 2021-01-18 2023-01-13 イビデン株式会社 Heat transfer suppression sheet for assembled battery and assembled battery
AU2022255506A1 (en) 2021-04-08 2023-11-09 Marengo Therapeutics, Inc. Multifunctional molecules binding to tcr and uses thereof

Family Cites Families (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DK0463151T3 (en) 1990-01-12 1996-07-01 Cell Genesys Inc Generation of xenogenic antibodies
GB9015908D0 (en) 1990-07-19 1990-09-05 Celltech Ltd Multivalent immunoglobulin
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
ATE314479T1 (en) 1992-05-18 2006-01-15 Genentech Inc ACTIVATION OF RECEPTORS CAPABLE OF OLIGOMERIZATION BY USING FUSIONED RECEPTOR LIGANDS
DK0614984T4 (en) 1993-03-05 2010-12-20 Bayer Healthcare Llc Human monoclonal anti-TNF alpha antibodies
CA2139385C (en) 1994-02-04 2001-12-25 Gottfried Alber Products containing g-csf and tnf binding protein
AU697387C (en) 1994-09-16 2006-03-02 Austin Research Institute Cancer and Anti-inflammatory Syndicate No 1 Polypeptides with Fc binding ability
US8791237B2 (en) 1994-11-08 2014-07-29 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of non-hodgkins lymphoma
ATE268604T1 (en) 1995-01-26 2004-06-15 Biogen Inc LYMPHOTOXIN-ALPHA/BETA COMPLEXES AND ANTIBODIES AGAINST THE LYMPHOTOXIN-BETA RECEPTOR AS AGENT AGAINST TUMORS
IL116784A (en) 1996-01-16 2000-01-31 Hadasit Med Res Service Device for examining viscoelasticity of a living or artificial tissue
US8212004B2 (en) 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
US6342369B1 (en) 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
US20060269558A1 (en) 1998-04-27 2006-11-30 Murphy Gerald P Nr-CAM gene, nucleic acids and nucleic acid products for therapeutic and diagnostic uses for tumors
SK288176B6 (en) 1999-01-07 2014-04-02 Zymogenetics, Inc. Pharmaceutical composition comprising fused protein, isolated polynucleotide molecule, expression vector, cultivated cell, method for preparing polypeptide and isolated polypeptide
AU774845B2 (en) 1999-03-04 2004-07-08 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6alpha and 6beta
CA2367315A1 (en) 1999-03-11 2000-09-14 Human Genome Sciences, Inc. Apoptosis inducing molecule ii and methods of use
WO2004009618A2 (en) 2002-07-18 2004-01-29 Crucell Holland B.V. Recombinant production of mixtures of antibodies
DE19963859A1 (en) 1999-12-30 2001-07-12 Apotech Res & Dev Ltd Bi- or oligomer of a di-, tri-, quattro- or pentamer of recombinant fusion proteins
US7262005B1 (en) 2000-02-04 2007-08-28 Aurora Biosciences Corporation Methods of protein destabilization and uses thereof
HUP0300369A2 (en) 2000-04-11 2003-06-28 Genentech, Inc. Multivalent antibodies and uses therefor
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
AU2001272978A1 (en) 2000-06-23 2002-01-08 Maxygen, Inc. Novel co-stimulatory molecules
WO2002004522A2 (en) 2000-07-10 2002-01-17 Novartis Ag Bifunctional molecules and vectors complexed therewith for targeted gene delivery
US6955717B2 (en) 2001-05-01 2005-10-18 Medimmune Inc. Crystals and structure of Synagis Fab
AU2002256895B2 (en) * 2001-05-18 2008-09-18 Kirin Beer Kabushiki Kaisha Anti-TRAIL-R antibodies
EP1401999A4 (en) 2001-05-25 2005-09-14 Amgen Inc B7 related protein-2 molecules and uses thereof
US20050214210A1 (en) * 2001-05-25 2005-09-29 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
EP1532244A4 (en) 2001-06-14 2005-12-14 Bristol Myers Squibb Co Novel human histone deacetylases
JP2005516958A (en) 2001-12-20 2005-06-09 ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド Antibodies that immunospecifically bind to TRAIL receptors
GB0220205D0 (en) 2002-08-30 2002-10-09 Chiron Spa Neisseria toxin
KR100915257B1 (en) 2002-11-27 2009-09-03 아이알엠 엘엘씨 A monoclonal anti-dr5 agonist antibody, an isolated cell expressing the antibody, a pharmaceutical composition comprising the antibody, and a method of using the antibody
AU2003303889A1 (en) 2003-01-07 2004-08-30 Biomerieux Polypeptides f' of the hepatitis c virus, epitopes, and the diagnostic and therapeutic applications thereof
EP1652925B1 (en) 2003-07-15 2010-12-08 Chugai Seiyaku Kabushiki Kaisha IgM PRODUCTION BY TRANSFORMED CELLS AND METHODS FOR QUANTIFYING SAID IgM PRODUCTION
ATE374035T1 (en) 2003-08-01 2007-10-15 Enhan Technology Holdings Inte EFFECTS OF SPORODERM-BREAKED GERMINATION-ACTIVATED GANODERMA SPORES ON THE TREATMENT OF SPINAL CORD INJURY AND THE PROLIFERATION AND/OR DIFFERENTIATION OF NEURAL STEM CELLS IN INJURED SPINAL CORD
CN100427505C (en) 2004-08-19 2008-10-22 中国医学科学院基础医学研究所 Receptor DR5 monoclonal antibody (AD5-10) resisting human tumor necrosin related apoptosis inducing ligand and its prepn and use
ES2551502T3 (en) 2004-11-05 2015-11-19 Igm Biosciences, Inc. Wound formation in the antibody-induced cell membrane
EP1833848A2 (en) 2004-12-09 2007-09-19 Lajolla Institute for Allergy and Immunology Novel tnf receptor regulatory domain
US8563004B2 (en) 2005-01-21 2013-10-22 Epitopix Llc Yersinia spp. polypeptides and methods of use
US8029783B2 (en) * 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
US20060269556A1 (en) 2005-04-18 2006-11-30 Karl Nocka Mast cell activation using siglec 6 antibodies
PE20061324A1 (en) 2005-04-29 2007-01-15 Centocor Inc ANTI-IL-6 ANTIBODIES, COMPOSITIONS, METHODS AND USES
US8088908B2 (en) 2005-05-10 2012-01-03 City Of Hope Humanized anti-prostate stem cell antigen monoclonal antibody
US20060269567A1 (en) 2005-05-16 2006-11-30 Liu Yuen Universal detoxifying composition
US20060269569A1 (en) 2005-05-16 2006-11-30 Liu Yuen Universal antioncotic and pain relieving ointment
EP1885401B1 (en) 2005-05-24 2015-07-22 The United States of America as represented by The Secretary of The Navy Anti-adhesin based passive immunoprophylactic against enterotoxigenic escherichia coli
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
PE20071101A1 (en) 2005-08-31 2007-12-21 Amgen Inc POLYPEPTIDES AND ANTIBODIES
TW200732350A (en) 2005-10-21 2007-09-01 Amgen Inc Methods for generating monovalent IgG
TWI461436B (en) 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd Human monoclonal antibody human cd134 (ox40) and methods of making and using same
AU2007230868B2 (en) 2006-01-13 2012-02-02 Irm Llc Antibodies against thymic stromal lymphopoietin receptor for treating allergic diseases
CN101074261A (en) 2006-04-30 2007-11-21 北京同为时代生物技术有限公司 TRAIL receptor I and/or TRAIL receptor 2 specific antibody and its use
AU2007252295B2 (en) 2006-05-19 2013-07-25 Central Adelaide Local Health Network Incorporated Selective modulation of receptor signalling
CA2654317A1 (en) 2006-06-12 2007-12-21 Trubion Pharmaceuticals, Inc. Single-chain multivalent binding proteins with effector function
KR100847010B1 (en) 2006-07-05 2008-07-17 아주대학교산학협력단 5 5 antibody binding specifically to dr5 and composition for preventing or treating a cancer comprising the same
EP1894940A1 (en) 2006-08-28 2008-03-05 Apogenix GmbH TNF superfamily fusion proteins
CN101512008B (en) 2006-09-08 2015-04-01 艾伯维巴哈马有限公司 Interleukin-13 binding proteins
GB0620894D0 (en) 2006-10-20 2006-11-29 Univ Southampton Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
EP2078040B1 (en) 2006-11-02 2017-06-28 Daniel J. Capon Methods of producing hybrid polypeptides with moving parts
AU2007358569B2 (en) 2007-09-07 2014-09-04 Ablynx N.V. Binding molecules with multiple binding sites, compositions comprising the same and uses thereof
CA2706700A1 (en) 2007-11-08 2009-05-14 Cytimmune Sciences, Inc. Compositions and methods for generating antibodies
WO2009106073A2 (en) 2008-02-28 2009-09-03 Dako Denmark A/S Mhc multimers in borrelia diagnostics and disease
EP2322220B1 (en) 2008-08-01 2014-01-01 Axis, Inc. Therapeutic agent or preventive agent for osteoarthritis
WO2010037402A1 (en) 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
JP5851419B2 (en) 2009-12-29 2016-02-03 エマージェント プロダクト デベロップメント シアトル， エルエルシー Heterodimer binding proteins and uses thereof
WO2011116387A1 (en) 2010-03-19 2011-09-22 Tetragenetics, Inc. Production of aglycosylated monoclonal antibodies in ciliates
KR20130010123A (en) 2010-04-07 2013-01-25 아비에 인코포레이티드 TNF-α BINDING PROTEINS
KR101527300B1 (en) 2010-09-09 2015-06-09 화이자 인코포레이티드 4-1bb binding molecules
CN103282495B (en) 2010-10-29 2017-06-09 第一三共株式会社 New Anti-DR5 antibody
EP2655415A4 (en) 2010-12-22 2016-03-09 Abbvie Inc Tri-variable domain binding proteins and uses thereof
KR101734614B1 (en) 2011-04-21 2017-05-12 브리스톨-마이어스 스큅 컴퍼니 Antibody polypeptides that antagonize cd40
GB201115280D0 (en) 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
GB201116092D0 (en) 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
EP2760891B1 (en) * 2011-09-26 2018-11-07 JN Biosciences LLC Hybrid constant regions
US9382319B2 (en) * 2011-09-26 2016-07-05 Jn Biosciences Llc Hybrid constant regions
CN104185641A (en) 2011-10-24 2014-12-03 艾伯维公司 Bispecific immunobinders directed against TNF and IL-17
US9409976B2 (en) 2012-02-08 2016-08-09 Igm Biosciences, Inc. CDIM binding proteins and uses thereof
EP2684896A1 (en) 2012-07-09 2014-01-15 International-Drug-Development-Biotech Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof
DK3415167T3 (en) 2012-08-01 2024-09-02 Nationwide Childrens Hospital INTRATHECAL ADMINISTRATION OF RECOMBINANT ADENOASSOCIATED VIRUS 9
US9540442B2 (en) 2012-08-02 2017-01-10 Jn Biosciences Llc Antibodies or fusion proteins multimerized via cysteine mutation and a mu tailpiece
WO2014063368A1 (en) 2012-10-26 2014-05-01 中国医学科学院基础医学研究所 Humanized monoclonal antibody in extracellular domain of anti-human death receptor 5
US9487773B2 (en) 2013-03-01 2016-11-08 Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa Cell-based methods for coupling protein interactions and binding molecule selection
UA118028C2 (en) 2013-04-03 2018-11-12 Рош Глікарт Аг Bispecific antibodies specific for fap and dr5, antibodies specific for dr5 and methods of use
MX2015014538A (en) * 2013-05-07 2016-02-05 Hoffmann La Roche Trimeric antigen binding molecules.
US20150038682A1 (en) 2013-08-02 2015-02-05 Jn Biosciences Llc Antibodies or fusion proteins multimerized via homomultimerizing peptide
AU2014332458B2 (en) 2013-09-05 2020-03-12 Igm Biosciences, Inc. Constant chain modified bispecific, penta- and hexavalent Ig-M antibodies
WO2015037000A1 (en) 2013-09-11 2015-03-19 Compugen Ltd Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases
BR112016015140A2 (en) 2013-12-30 2018-01-23 Epimab Biotherapeutics Inc. tandem-fab immunoglobulin and its uses
AU2015206002B2 (en) 2014-01-16 2020-06-11 Mario Umberto Francesco MONDELLI Neutralizing human monoclonal antibodies against Hepatitis B Virus surface antigen
WO2015120474A1 (en) 2014-02-10 2015-08-13 Igm Biosciences, Inc. Iga multi-specific binding molecules
JP6682498B2 (en) 2014-03-24 2020-04-15 キャンサー・リサーチ・テクノロジー・リミテッドＣａｎｃｅｒ Ｒｅｓｅａｒｃｈ Ｔｅｃｈｎｏｌｏｇｙ Ｌｉｍｉｔｅｄ Modified antibodies containing modified IgG2 domains that induce agonistic or antagonistic properties and uses thereof
IL278350B (en) 2014-04-03 2022-06-01 Igm Biosciences Inc Modified j-chain
JP6810687B2 (en) 2014-10-08 2021-01-06 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Combination therapy with FAP and DR5-specific bispecific antibodies and chemotherapeutic agents
SG11201705116SA (en) 2015-01-20 2017-08-30 Igm Biosciences Inc Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof
WO2016122702A1 (en) 2015-01-26 2016-08-04 Macrogenics, Inc. Multivalent molecules comprising dr5-binding domains
HUE054642T2 (en) 2015-03-04 2021-09-28 Igm Biosciences Inc Cd20 binding molecules and uses thereof
KR102558839B1 (en) 2015-03-25 2023-07-25 아이쥐엠 바이오사이언스 인코포레이티드 Multivalent hepatitis B virus antigen-binding molecules and uses thereof
AU2016249404B2 (en) 2015-04-17 2021-01-21 Igm Biosciences, Inc. Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof
WO2017004213A1 (en) 2015-06-30 2017-01-05 Sanford-Burnham Medical Research Institute Btla fusion protein agonists and uses thereof
AU2015242213A1 (en) 2015-07-12 2018-03-08 Hangzhou Dac Biotech Co., Ltd Bridge linkers for conjugation of cell-binding molecules
EP3355913B1 (en) 2015-09-30 2024-10-30 IGM Biosciences, Inc. Binding molecules with modified j-chain
CN108463472A (en) 2015-09-30 2018-08-28 Igm生物科学有限公司 The binding molecule of J- chains with modification
PT3455257T (en) 2016-05-09 2021-12-06 Igm Biosciences Inc Anti-pd-l1 antibodies
JP2019528683A (en) 2016-07-20 2019-10-17 アイジーエム バイオサイエンシズ インコーポレイテッド Multimeric GITR binding molecules and uses thereof
AU2017299608A1 (en) 2016-07-20 2019-02-07 Igm Biosciences, Inc. Multimeric CD137/4-1BB binding molecules and uses thereof
EP3496536A4 (en) 2016-07-20 2020-02-12 IGM Biosciences, Inc. Multimeric cd40 binding molecules and uses thereof
WO2018017888A1 (en) 2016-07-20 2018-01-25 Igm Biosciences, Inc. Multimeric ox40 binding molecules and uses thereof
WO2018056821A1 (en) 2016-09-23 2018-03-29 Merus N.V. Binding molecules that modulate a biological activity expressed by a cell
WO2018187702A2 (en) 2017-04-07 2018-10-11 Igm Biosciences A/S Modified human igm constant regions for modulation of complement-dependent cytolysis effector function
KR20200123782A (en) 2018-02-26 2020-10-30 아이쥐엠 바이오사이언스 인코포레이티드 Use of multiple bonded anti-DR5 binding molecules in combination with chemotherapeutic agents for cancer treatment
AU2019227984A1 (en) 2018-03-01 2020-09-10 Igm Biosciences, Inc. IgM Fc and J-chain mutations that affect IgM serum half-life
US20210380701A1 (en) 2018-10-23 2021-12-09 Igm Biosciences, Inc. MULTIVALENT IgM- AND IgA-Fc-BASED BINDING MOLECULES
WO2020163646A1 (en) 2019-02-08 2020-08-13 Igm Biosciences, Inc. Anti-gitr antigen-binding domains and uses thereof
US20230203119A1 (en) 2019-08-15 2023-06-29 Igm Biosciences, Inc. Immunostimulatory multimeric binding molecules
CA3147767A1 (en) 2019-08-17 2021-02-25 Igm Biosciences, Inc. Multimeric bispecific anti-cd123 binding molecules and uses thereof
CN114269380A (en) 2019-08-23 2022-04-01 Igm生物科学股份有限公司 IgM sugar variants
AU2020351205A1 (en) 2019-09-19 2022-04-14 Igm Biosciences, Inc. Multimeric antibodies with enhanced selectivity for cells with high target density
WO2021141902A1 (en) 2020-01-06 2021-07-15 Igm Biosciences, Inc. Highly sialylated multimeric binding molecules
CN115485299A (en) 2020-04-22 2022-12-16 Igm生物科学股份有限公司 PD-1 agonist multimeric binding molecules
WO2021231639A1 (en) 2020-05-12 2021-11-18 Igm Biosciences, Inc. Use of a multimeric anti-dr5 binding molecule in combination with a cancer therapy for treating cancer
AU2021315513A1 (en) 2020-07-27 2023-03-02 Igm Biosciences, Inc. Multimeric coronavirus binding molecules and uses thereof
US20240002526A1 (en) 2020-11-17 2024-01-04 Igm Biosciences, Inc. Uses of effector cell engaging molecules with moieties of differing potencies
US20220267415A1 (en) 2021-02-17 2022-08-25 The Board Of Regents Of The University Of Texas System Multimeric sars-cov-2 binding molecules and uses thereof
WO2022178047A1 (en) 2021-02-17 2022-08-25 Igm Biosciences, Inc. Anti-cd123 binding molecules and uses thereof

Also Published As

Publication number Publication date
CA2972990A1 (en) 2016-07-28
AU2016209324A1 (en) 2017-07-06
IL253054B (en) 2021-08-31
JP2022177090A (en) 2022-11-30
SG10202001779UA (en) 2020-04-29
EP3247728A4 (en) 2018-07-04
AU2020201323B2 (en) 2022-03-31
AU2020201323A1 (en) 2020-03-12
CN107207601A (en) 2017-09-26
IL253054A0 (en) 2017-08-31
IL284430A (en) 2021-07-29
DK3247728T3 (en) 2020-07-13
SI3247728T1 (en) 2020-09-30
ES2806500T3 (en) 2021-02-17
EP3247728B1 (en) 2020-04-15
JP2024113039A (en) 2024-08-21
IL308212A (en) 2024-01-01
PL3247728T3 (en) 2020-11-16
JP2018503401A (en) 2018-02-08
JP7179464B2 (en) 2022-11-29
KR102435324B1 (en) 2022-08-23
IL284430B1 (en) 2023-12-01
US20210047419A1 (en) 2021-02-18
US20230203173A1 (en) 2023-06-29
US11578131B2 (en) 2023-02-14
PT3247728T (en) 2020-07-16
US20180009897A1 (en) 2018-01-11
JP7499813B2 (en) 2024-06-14
EP3247728A1 (en) 2017-11-29
WO2016118641A1 (en) 2016-07-28
EP3750918A1 (en) 2020-12-16
US20170320955A1 (en) 2017-11-09
NZ732922A (en) 2022-07-29
US10689449B2 (en) 2020-06-23
IL284430B2 (en) 2024-04-01
AU2016209324B2 (en) 2020-02-27
US9938347B2 (en) 2018-04-10
KR20170105077A (en) 2017-09-18
JP2021006044A (en) 2021-01-21
HUE051013T2 (en) 2021-01-28

Similar Documents

Publication Publication Date Title
IL284430A (en) Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof
ZA202003741B (en) Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
HK1252957A1 (en) Tgf-beta superfamily type i and type ii receptor heteromultimers and uses thereof
IL259399A (en) Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
IL263799A (en) Multimeric ox40 binding molecules and uses thereof
IL254223A (en) Cd20 binding molecules and uses thereof
IL251891A0 (en) Binding molecules specific for cd73 and uses thereof
SG11201704597WA (en) Agonistic tnf receptor binding agents
SG10202111844VA (en) Cxcr4 binding molecules
EP3315513A4 (en) Cd154 binding polypeptide and use thereof
GB201811410D0 (en) OX40 Binding molecules
IL259883A (en) Antibody molecules which bind tnf alpha
IL252669B (en) Agonistic tnf receptor binding agents